ati-2173
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04248426)
Timeline
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05238844 | Phase 2 | Apr 11, 2022 | Antios Therapeutics, Inc |
| NCT05298332 | Phase 1 | Mar 29, 2022 | Antios Therapeutics, Inc |
| NCT05137600 | Phase 1 | Oct 28, 2021 | Antios Therapeutics, Inc |
| NCT05137548 | Phase 1 | Oct 27, 2021 | Antios Therapeutics, Inc |
| NCT04847440 | Phase 2 | Mar 30, 2021 | Antios Therapeutics, Inc |
| NCT04248426 | Phase 1 | Feb 29, 2020 | Antios Therapeutics, Inc |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antios Therapeutics, Inc | For profit | 6 | 6 | 2 | 2020 |
1 organizations
Page 1 / 1